Disease relevance of Endpoint Determination

• Nasal potential difference measurements are valuable endpoint assays in clinical studies of novel treatments for cystic fibrosis (CF) [1].

High impact information on Endpoint Determination

• Many attempts have been made to design universal ligand-screening systems such that any GPCR can be screened using a common assay end-point [2].
• With the three endpoint assays, each of which was applied 12 times at 2-hour intervals, maximum apoptotic responses varied from 22.5 to 72% in etoposide-treated cells and from 30 to 57% in cisplatin-treated cells [3].
• To detect activated Stat5 in CML patient specimens, we developed an immunocytochemical assay that can be used as a molecular end-point assay to monitor inhibition of Bcr-Abl signaling [4].
• Potential difference measurements could form a useful functional endpoint assay for future studies of either the CFTR gene or protein-based therapies in future trials in the pediatric age group [1].
• Tumor samples were tested for sensitivity to Apomine, carboplatin, cisplatin, paclitaxel, and topotecan using an in vitro clonogenic [(3)H]thymidine end point assay [5].

Biological context of Endpoint Determination

• Phenolphthalein is liberated by the enzymatic hydrolysis of the substrate (phenolphthalein monophosphate) and the absorbance generated is measured as the assay end-point [6].

Anatomical context of Endpoint Determination

• Whereas the interleukin-8 induced locomotory changes were correctly represented by end point determination, relatively slight but significant modulation in lymphocyte behaviour by anti-integrin antibodies was revealed solely by analysis of the complete cell trajectory [7].

Associations of Endpoint Determination with chemical compounds

• MIC end point determination for the most commonly prescribed azole antifungal drug, fluconazole, can be complicated by "trailing" growth of the organism during susceptibility testing by the National Committee for Clinical Laboratory Standards approved M27-A broth macrodilution method and its modified broth microdilution format [8].
• Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates [9].
• The endpoint determination of cholesterol combines the unique blanking capabilities of the centrifugal analyzer to correct for sample and reagent blank interferences [10].
• The pyruvate method is an end-point assay, because endogenous lactate dehydrogenase interferes in a kinetic pyruvate assay [11].
• An early-reading blank-corrected end-point determination of uric acid in serum has been developed for use with a centrifugal analyzer [12].

Gene context of Endpoint Determination

• Lysyl oxidase activity in biological samples is traditionally and most reliably assessed by tritium release end-point assays using radiolabeled collagen or elastin substrates involving laborious vacuum distillation of the released tritiated water [13].
• The advantages of this assay include the use of noninfectious antigens, the requirement for only small quantities of serum, the capability of screening large numbers of sera, the speed of execution, and the objectivity of end point determination [14].
• There was close agreement of endpoint determinations of sera by both methods [15].
• Accurate end-point determinations of the maximally oxygenated and deoxygenated myoglobin were made [16].
• Monoclonal antibody 47-10/10, prepared using D80-100 virus and directed at the NS1 non-structural glycoprotein, had a significantly lower (100-fold) solid phase radioimmune assay endpoint titre for D80-141 antigen than for D80-100 antigen [17].

Analytical, diagnostic and therapeutic context of Endpoint Determination

• Employing biotin as the primary probe in a competitive solid phase immunoassay allows for variable end point determination by means of commercially available labeled avidin or streptavidin derivatives [18].
• The use of 3,3',5,5' - tetramethylbenzidine as non-mutagenic chromogen for the end point determination in enzyme-immunoassay (EIA) is described [19].

References